Clinical Trial Update: Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial update on an HIV-1 vaccine (VRC-HIVRGP096-00-VP) with alum in healthy adults, focusing on dose, safety, tolerability, and immunogenicity; study co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Prevention
• Human Immunodeficiency Virus Infection

Drugs mentioned

• VRC-HIVRGP096-00-VP

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV) | Phase 1 | Status: COMPLETED | Results posted: 2021-08-12